Glucagon-Like Peptide 1Hypoglycemic AgentsReceptors, GlucagonSulfonylurea CompoundsVenomsMetforminDiabetes Mellitus, Type 2Pancreatic alpha-AmylasesHemoglobin A, GlycosylatedIncretinsBlood GlucoseCandyPyrazinesInsulin, Long-ActingDipeptidyl-Peptidase IV InhibitorsDrug SubstitutionTriazolesWeight LossAnti-Obesity AgentsAdamantaneDrug Therapy, CombinationBody WeightClinical Trials, Phase III as TopicDipeptidyl Peptidase 4HypoglycemiaPlacebosAppetite DepressantsDrug Administration ScheduleDiet, High-FatInjections, SubcutaneousPeptidesGlucagon-Secreting CellsMetabolic Detoxication, DrugSafetyThiazolidinedionesRats, ZuckerPrediabetic StateTreatment OutcomeGlucagonInsulin-Secreting CellsGastric EmptyingQuality-Adjusted Life YearsDouble-Blind MethodInsulinWeight GainMulticenter Studies as TopicRandomized Controlled Trials as TopicAdiposityHyperinsulinismCost-Benefit AnalysisMeta-Analysis as TopicFastingObesityMicrodissectionEatingHyperglycemiaNeprilysinPancreasC-PeptideNew ZealandHalf-LifeIntra-Abdominal FatGlucose Tolerance TestPancreatitisFatty LiverIslets of LangerhansFeeding BehaviorBody Mass IndexNauseaInsulin ResistanceDisease Models, AnimalAdiponectinTreatment FailureAsian Continental Ancestry GroupJapanCardiomegalyGene Knockdown TechniquesDiabetic NephropathiesTime FactorsApolipoproteins EMice, Inbred C57BLCross-Over StudiesBiological MarkersPatient SatisfactionDose-Response Relationship, DrugGlucoseEnzyme-Linked Immunosorbent AssayLiverRats, Sprague-DawleyAnalysis of Variance